证券代码：688278 证券简称：特宝生物 公告编号：2024-015 厦门特宝生物工程股份有限公司关于 参加 2023 年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 4 月 12 日（星期五）16:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱ir@amoytop.com进行提问，公司将 在说明会上对投资者普遍关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日在上海证券交易所披露了公司 2023 年年度报告，为便于广大投资者更全面深 入地了解公司 2023 年度经营成果、财务状况和发展理念，公司参加了由上海证 券交易所主办的 2023 年度生物制品专场集体业绩说明会，此次活动将采用视频 和网络文字互动的方式举行，欢迎广大投资者积极参与。公司现就 2023 年度业 绩说明会提前向广大投资者征集相关问题，广泛听取投资者的意见和建议。 一、说明会类型 本次业绩说明会以 ...

证券代码：688278 证券简称：特宝生物 公告编号：2024-014 厦门特宝生物工程股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2024 年 4 月 29 日 14 点 00 分 召开地点：厦门市海沧新阳工业区翁角路 330 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 4 月 29 日 至 2024 年 4 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者 ...

2024 年 04 月 04 日 公司研究 评级：买入 (维持 ) 研究所： [Table_Title] 公司 年业绩高速成长，创新产品持续兑现 2023 证券分析师： 周小刚 S0350521090002 zhouxg@ghzq.com.cn 联系人 ： 年庆功 S0350122030007 ——特宝生物（ ） 年年报点评报告 688278 2023 nianqg@ghzq.com.cn 最近一年走势 事件 : 2024年3月29日，特宝生物发布2023年年报：2023年公司营业收入 21.00亿元（yoy+37.55%），归母净利润5.55亿元（yoy+93.52%）， 扣非归母净利润5.79亿元（yoy+73.58%）。 投资要点 :  公司2023年业绩高速增长。 2023年公司营业收入21.00亿元 相对沪深300表现 2024/04/03 （yoy+37.55%），归母净利润5.55亿元（yoy+93.52%），扣非归 表现 1M 3M 12M 母净利润5.79亿元（yoy+73.58%）。2023年Q4公司营业收入6.41 特宝生物 8.2% 24.7% 47.6% 亿元（yoy+66.93% ...

国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 首次公开发行股票并在科创板上市之持续督导保荐总结报告书 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程股 份有限公司（以下简称"特宝生物"或"公司"）首次公开发行股票并在科创板 上市的保荐机构，根据《证券发行上市保荐业务管理办法》等有关规定，对特宝 生物首次公开发行股票并在科创板上市进行尽职推荐和持续督导，持续督导期限 自2020年1月17日至2023年12月31日。目前，持续督导期限已满，本保荐机构根 据《证券发行上市保荐业务管理办法》的有关规定对特宝生物出具保荐总结报告 书，具体情况如下： 一、保荐机构基本情况 | 项目 | 内容 | | --- | --- | | 保荐机构 | 国金证券股份有限公司 | | 注册地址 | 成都市青羊区东城根上街95号 | | 主要办公地址 | 上海市浦东新区芳甸路1088号紫竹国际大厦23楼 | | 法定代表人 | 冉云 | | 保荐代表人 | 邓晓艳、阮任群 | | 联系电话 | 021-68826021 | 二、发行人基本情况 | 项目 | 内容 | | --- | --- | | 发行人名称 ...

公司代码：688278 公司简称：特宝生物 厦门特宝生物工程股份有限公司 投资者关系活动记录表 ...

公 司 研 究 [Table_Reportdate] 2024年04月02日 [Table_invest] [特Tabl宝e_N生ewT物itle] （688278）：公司业绩超预期， 买入（维持） 公 派格宾新适应症值得期待 司 报告原因：业绩点评 简 ——公司简评报告 评 [table_main] [证Ta券b分le析_A师u thors] 投资要点 杜永宏 S0630522040001 dyh@longone.com.cn ➢ 公司业绩超预期，盈利能力持续增强。2023年，公司实现营业收入21.00亿元（+37.55%）、 医 证券分析师 归母净利润5.55亿元（+93.52%）、扣非净利润5.79亿元（+73.58%）。其中Q4单季实现收 药 伍可心 S0630522120001 生 wkx@longone.com.cn 入6.41亿元（+66.93%），归母净利润1.87亿元（+115.37%）。公司收入端随着核心产品派 联系人 格宾持续放量快速增长，利润端因毛利率的提升和费用率的下降实现高速增长。从期间费 物 付婷 用上看，销售费用率为40.41%，同比下降5.64pp；管理费用率为10.01%， ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant increase in revenue and net profit for the fiscal year 2023, with revenue reaching 2.1 billion yuan, a year-on-year growth of 37.55%, and net profit attributable to shareholders at 555 million yuan, a year-on-year increase of 93.52% [1][2] - The company has shown strong operational efficiency with a gross margin of 93.33%, up by 4.42 percentage points year-on-year, and a net profit margin of 26.4%, which is an increase of 7.6 percentage points compared to the previous year [1] - The company is actively expanding its market share in the hepatitis B treatment sector, particularly with its product Peginterferon, which has been well-received in the market [1][2] Financial Performance Summary - For 2023, the company achieved a revenue of 2.1 billion yuan, with a year-on-year growth of 37.6% [3] - The projected revenues for 2024, 2025, and 2026 are 2.723 billion yuan, 3.537 billion yuan, and 4.379 billion yuan respectively, with expected growth rates of 29.6%, 29.9%, and 23.8% [2][3] - The net profit attributable to shareholders for 2024, 2025, and 2026 is projected to be 768 million yuan, 1.052 billion yuan, and 1.355 billion yuan, reflecting year-on-year growth rates of 38.3%, 37.0%, and 28.8% [2][3] - The company maintains a high gross margin, projected to increase to 94.6% in 2024 and 96.7% in 2026 [3][4] Market Position and Growth Potential - The company is positioned as a pioneer in the hepatitis B treatment market, with ongoing academic promotion plans that are expected to drive long-term growth [1][2] - The company has successfully completed Phase III clinical trials for its product and has submitted a marketing application to the National Medical Products Administration (NMPA) [1] - The expansion of the patient population for its hepatitis B treatment is expected to further enhance the company's market presence [1][2]

Investment Rating - The report assigns a "Recommended" rating for the company, marking the first coverage [1]. Core Insights - The company achieved a revenue of 2.1 billion in 2023, representing a year-on-year growth of 37.55%. The net profit attributable to shareholders was 555 million, up 93.52% year-on-year [1][12]. - The core product, Pegasys, saw a revenue of 1.79 billion, with a year-on-year growth of 54.18%, and a sales volume of 2.8467 million units, reflecting a growth of 46.68% [1][16]. - The company is focused on enhancing its R&D capabilities, with R&D investment reaching 280 million in 2023, a 34.96% increase year-on-year [1][19]. Summary by Sections Company Performance - In 2023, the company reported a total revenue of 2.1 billion, with a net profit of 555 million, and a significant increase in operating cash flow by 41.01% to 512 million [1][12]. - The gross margin for 2023 was 93.33%, an increase of 4.41 percentage points year-on-year, while the net margin rose to 26.45%, up 7.65 percentage points [12][16]. Product Development - Pegasys remains the company's core product, accounting for 85.24% of total revenue in 2023, with a gross profit contribution of 87.24% [16][27]. - The company is advancing its clinical trials for new indications, with the registration application for chronic hepatitis B treatment recently accepted [1][27]. Financial Forecast - The company expects revenues of 2.827 billion, 3.670 billion, and 4.584 billion for 2024, 2025, and 2026, respectively, with corresponding net profits of 760 million, 1.025 billion, and 1.311 billion [29][31]. - The projected growth rates for revenue are 35%, 30%, and 25% for the years 2024 to 2026 [31]. Valuation Analysis - The current stock price corresponds to a PE ratio of 33, 25, and 19 for the years 2024 to 2026, indicating a favorable valuation compared to peers [29][31]. - The report suggests a valuation premium due to the company's leading position in the hepatitis B treatment market and the low penetration rate of Pegasys [29][31].

Investment Rating - The report does not specify a direct investment rating for the company, but it suggests that investors should pay attention to the company due to its strong growth prospects and leading position in the hepatitis B treatment market [2][8]. Core Insights - The company achieved a revenue of 2.1 billion yuan in 2023, representing a growth of 37.6%, and a net profit attributable to shareholders of 560 million yuan, which is an increase of 93.5% [2]. - The rapid growth in sales of the drug Paigebin is attributed to its recognition as a first-line antiviral treatment for chronic hepatitis B, which has improved clinical cure rates and reduced liver cancer risks [2]. - The company has increased its R&D investment to 280 million yuan, a growth of 34.96%, and is advancing multiple projects in its pipeline, including a new long-acting recombinant human granulocyte colony-stimulating factor [2][8]. - The projected net profits for 2024-2026 are 790 million, 1.07 billion, and 1.37 billion yuan, respectively, indicating strong future growth [2][8]. Summary by Sections Financial Performance - In 2023, the company reported a revenue of 2.1 billion yuan, with a net profit of 560 million yuan, reflecting significant growth rates of 37.6% and 93.5% respectively [2][12]. - The gross margin improved to 93.3%, up by 4.4 percentage points, and the net profit margin after excluding non-recurring items reached 27.6%, an increase of 5.7 percentage points [2][12]. R&D and Pipeline Development - The company invested 280 million yuan in R&D in 2023, marking a 34.96% increase [2]. - Key projects in the pipeline include YPEG-GH, which has completed Phase III clinical trials, and YPEG-EPO, which is preparing for Phase III clinical application [2][8]. Profit Forecast - The forecasted net profits for the company are 790 million yuan in 2024, 1.07 billion yuan in 2025, and 1.37 billion yuan in 2026, with corresponding growth rates of 42.33%, 35%, and 28.8% [2][12].

本报告仅供 Choice 东方财富 使用，请勿传阅。 公司快报 2024 年 03 月 31 日 特 宝生物(688278.SH) 证券研究报告 长效干扰素持续放量，长效升白药、长 生物医药Ⅲ 投资评级 买入-A 效生长激素逐渐进入商业化兑现阶段 维持评级 6个月目标价 65.90元 事件：公司发布 2023年年报，报告期内公司实现营收 21.00亿 股价 (2024-03-29) 61.95元 元，同比增长 37.55%；实现归母净利润 5.55 亿元，同比增长 93.52%；实现扣非归母净利润 5.79亿元，同比增长 73.58%。 交易数据 总市值(百万元) 25,201.26 长效干扰素驱动业绩增长，增加适应症有望加速放量。2023年 流通市值(百万元) 25,201.26 公司长效干扰素派格宾销售收入 17.90 亿元，同比增长 54.2%， 总股本(百万股) 406.80 占总营收 85.2%。公司稳步推进以临床治愈为目标的慢乙肝确证 流通股本(百万股) 406.80 性临床试验，派格宾联合核苷（酸）类似物针对成人慢乙肝增加 12个月价格区间 31.2/69.7元 适应症的上市许可申请，已于 20 ...